561
Participants
Start Date
April 30, 2001
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2011
Alprostadil (Prostaglandin E1)
"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
Pentoxifylline
"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
Placebo to Pentoxifylline oral
"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
Placebo to Alprostadil (Prostaglandin E1) intravenous
"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
Aachen
Bad Säckingen
Berlin
Bottrop
Cologne
Dortmund
Dresden
Düsseldorf
Essen
Essen-Steele
Freiburg im Breisgau
Gaggenau
Görlitz
Hamburg
Hanover
Hattingen
Heidelberg
Homburg
Jena
Karlsbad-Lang Ensteinbach
Kassel
Krefeld
Leipzig
Lüneburg
Mannheim
Mannheim-Lindenhof
Mönchengladbach
München
Neuss
Nuremberg
Osnabrück
Papenburg
Regensburg
Seesen
Warendorf
Wuppertal
Lead Sponsor
UCB Pharma
INDUSTRY